Multidrug-resistant tuberculosis in central Asia

被引:49
作者
Cox, HS
Orozco, JD
Male, R
Ruesch-Gerdes, S
Falzon, D
Small, I
Doshetov, D
Kebede, Y
Aziz, M
机构
[1] Med Sans Frontieres, Aral Sea Area Programme, Tashkent 700000, Uzbekistan
[2] Natl Reference Ctr Mycobacteria, Borstel, Germany
[3] Minist Hlth, Karakalpekstan, Uzbekistan
[4] WHO, CH-1211 Geneva, Switzerland
关键词
D O I
10.3201/eid1005.030718
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Medecins Sans Frontieres in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB.
引用
收藏
页码:865 / 872
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 1997, WHOTB96216
[2]  
*EC INT UN, 2002, COUNTR REP
[3]   Standard short-course chemotherapy for drug-resistant tuberculosis -: Treatment outcomes in 6 countries [J].
Espinal, MA ;
Kim, SJ ;
Suarez, PG ;
Kam, KM ;
Khomenko, AG ;
Migliori, GB ;
Baéz, J ;
Kochi, A ;
Dye, C ;
Raviglione, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19) :2537-2545
[4]   Global trends in resistance to antituberculosis drugs [J].
Espinal, MA ;
Laszlo, A ;
Simonsen, L ;
Boulahbal, F ;
Kim, SJ ;
Reniero, A ;
Hoffner, S ;
Rieder, HL ;
Binkin, N ;
Dye, C ;
Williams, R ;
Raviglione, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) :1294-1303
[5]  
*EUR OBS HLTH CAR, 2002, HLTH CAR CENTR AS, P179
[6]  
Farmer P, 1998, INT J TUBERC LUNG D, V2, P869
[7]  
Farmer Paul, 1999, GLOBAL IMPACT DRUG R
[8]  
Kent P.T., 1985, PUBLIC HLTH MYCOBACT
[9]  
Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P451
[10]   Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis [J].
Lockman, S ;
Kruuner, A ;
Binkin, NJ ;
Levina, K ;
Wang, YC ;
Danilovitsh, M ;
Hoffner, SE ;
Tappero, HW .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :373-380